A Phase 1 interventional study of Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Trospium Chloride
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Xanomeline MR
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline Enteric Capsule · Drug: Xanomeline MR
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline · Drug: Placebo
Drug: Xanomeline/Trospium Chloride Capsule · Drug: Xanomeline · Drug: Placebo
Drug pages: Xanomeline · Trospium chloride
Specified dose on specified days
Also known as: BMS-986510, KarXT
Specified dose on specified days
Also known as: BMS-986519, KarX-EC
Specified dose on specified days
Also known as: BMS-986520, KarT
Specified dose on specified days
Also known as: BMS-986519, KarX-MR
Specified dose on specified days
Also known as: BMS-986519, KarX
Specified dose on specified days
Maximum observed concentration (Cmax)
Time frame: Up to Day 23
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 23
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to Day 23
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to Day 23
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Time frame: Up to Day 23
Concentration at the end of a dosing interval (Ctau)
Time frame: Up to Day 23
Apparent total body clearance (CLT/F)
Time frame: Up to Day 23
Effective elimination half-life during dosing interval (T-HALF(eff))
Time frame: Up to Day 23
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with Serious Adverse Events (SAEs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with Adverse Events of Special Interest (AESIs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with AEs leading to discontinuation
Time frame: Up to 30 days after final dose of study intervention
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to Day 14
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with Serious Adverse Events (SAEs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with Adverse Events of Special Interest (AESIs)
Time frame: Up to 30 days after final dose of study intervention
Number of participants with AEs leading to discontinuation
Time frame: Up to 30 days after final dose of study intervention
Number of participants with vital signs abnormalities
Time frame: Up to 30 days after final dose of study intervention
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 30 days after final dose of study intervention
Number of participants with physical examination abnormalities
Time frame: Up to 30 days after final dose of study intervention
Number of participants with clinical laboratory abnormalities
Time frame: Up to 30 days after final dose of study intervention
Geometric mean ratio of Cmax
Time frame: Up to Day 12
Geometric mean ratio of AUC(0-T)
Time frame: Up to Day 12
Geometric mean ratio of AUC(INF)
Time frame: Up to Day 12
Geometric mean ratio of area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Time frame: Up to Day 12
Maximum observed concentration (Cmax)
Time frame: Up to Day 16
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 16
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to Day 16
Area under the plasma concentration-time curve from time zero to 12 hours (AUC(0-12))
Time frame: Up to Day 4
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to Day 23
Apparent total body clearance (CLT/F)
Time frame: Up to Day 16
Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
Time frame: Up to Day 16
Effective elimination half-life during dosing interval (T-HALF(eff))
Time frame: Up to Day 16
Cmax Accumulation Index: Ratio of Cmax at steady state to Cmax after first dose (AI_Cmax)
Time frame: Up to Day 16
AUC(TAU) Accumulation Index: Ratio of AUC(TAU) at steady state to AUC(TAU) after first dose (AI_AUC)
Time frame: Up to Day 16
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium chloride